The Precision Medicine by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Precision Medicine Market:
https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report
According to The Business Research Company’s Precision Medicine, The precision medicine market size has grown rapidly in recent years. It will grow from $73.11 billion in 2023 to $81.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increase in cancer prevalence, increasing prevalence of mental health disorders, increased prevalence of respiratory diseases, increasing funding, increased geriatric population, increase in pharmaceutical r&d expenditure and increased healthcare expenditure.
The precision medicine market size is expected to see strong growth in the next few years. It will grow to $118.08 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing geriatric population, increasing prevalence of cancer, high potential of emerging economies, emergence of novel pathogenic infestations, increasing research and development spending and rise in healthcare expenditure. Major trends in the forecast period include adopting artificial intelligence technologies for improving competitiveness, offering diagnosis and personalized treatment for immune-mediated diseases, investing in increased research and development activities and forming collaborations and partnerships with technology and healthcare entities to improve their product portfolios.
The rising prevalence of cancer is projected to fuel the growth of the precision medicine market. Cancer is one of the main causes of death worldwide, with one out of every five individuals developing cancer at some point in their lives. Precision medicine in cancer entails analyzing DNA from tumors to find mutations or other genetic abnormalities that cause cancer. Physicians may therefore be able to choose a treatment for a specific patient's cancer that best fits, or targets, the tumor DNA alterations. For instance, in April 2022, according to a report on cancer facts and figures by the American Cancer Society, a US-based nonprofit health organization devoted to the eradication of cancer, there were 1.92 million new cases of cancer in the US, compared to 1.89 cases in 2021. Therefore, the rising prevalence of cancer drives the growth of the precision medicine market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=5301&type=smp
The precision medicine market covered in this report is segmented –
1) By Technology: Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Other Technology
2) By Application: Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, Other Applications.
3) By End-Use: Pharmaceutical Companies, Diagnostic Companies, Healthcare And IT Firms, Others
The rising number of partnerships and acquisitions among precision medicine companies is enabling them to expand their approaches to both oncology and non-oncology areas. Precision medicine is undergoing continuous research and development in new areas, collaboration and partnership helps the firms to enhance their capabilities and approaches. For example, in August 2021, Foundation Medicine Inc. announced a partnership with Epic to integrate their comprehensive genomic profiling and other testing devices with the electronic medical record of Epic. The integration aims at simplifying the process of getting oncologists access to genomic insights and expanding the use of precision medicine to more cancer patients.
The precision medicine market report table of contents includes:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The global Precision Medicine Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the precision medicine market include Roche Holding AG, Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company and others..
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Precision Medicine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/precision-medicine-market/download-sampleMarket DynamicsThe market is mainly driven by increasing approval of the drug and its companion diagnostic assay, cost-effective profiling of DNA, increasing incidence of cancer, and the rise of data-driven healthcare.
In addition, the rising use of “multi-omics” in research, along with the penetration of high-throughput sequencing platforms, is also surging up the precision medicine scenario.
The number of targeted molecules in the pipeline for a specific application has been exponentially growing, specifically in oncology has created a new opportunity over the forecast period.
